NM404
PreclinicalSmall molecule
NM404 is one of 6 small molecule programs targeting Brain Tumors. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Brain Tumors
#DrugCompanyPhaseTrials
1Keppra
UCBPhase 3
Lumakras
AmgenPhase 1
Triostat
VViking Therapeutics, Inc.
Preclinical
5-Aminolevulinic Acid
DDavid W. Roberts
Phase 1
Fimepinostat
UUniversity of California, Los Angeles
Phase 1
NM404
UUniversity of Wisconsin, Madison
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NM404. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Wisconsin, Madison